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AbstRAct
Personalised medicine, new discoveries and studies on 
rare exposures or outcomes require large samples that 
are increasingly difficult for any single investigator to 
obtain. Collaborative work is limited by heterogeneities, 
both what is being collected and how it is defined. To 
develop a core set for data collection in rheumatoid 
arthritis (RA) research which (1) allows harmonisation of 
data collection in future observational studies, (2) acts as 
a common data model against which existing databases 
can be mapped and (3) serves as a template for 
standardised data collection in routine clinical practice to 
support generation of research-quality data. A multistep, 
international multistakeholder consensus process was 
carried out involving voting via online surveys and two 
face-to-face meetings. A core set of 21 items (’what to 
collect’) and their instruments (’how to collect’) was 
agreed: age, gender, disease duration, diagnosis of 
RA, body mass index, smoking, swollen/tender joints, 
patient/evaluator global, pain, quality of life, function, 
composite scores, acute phase reactants, serology, 
structural damage, treatment and comorbidities. The 
core set should facilitate collaborative research, allow 
for comparisons across studies and harmonise future 
data from clinical practice via electronic medical record 
systems.
IntRoductIon
Research questions of the current era require ever 
larger study populations which often exceed the 
number of patients available in individual studies 
or registries; hence, combined or pooled analyses 
are often required. Such collaborative work is, 
however, compromised by heterogeneities in the 
data collected.1 More recently, routinely collected 
data from electronic medical records (EMR) has 
the potential to support research, but there is no 
agreed set of data that would be desirable to collect 
in order to generate research-quality data if used 
beyond direct clinical care.
To facilitate collaborative research, standardising 
items (‘what to collect’) and their instruments (‘how 
to collect’) across studies and data collections is 
critical. Although guidelines on data reporting and 
outcome measures have been developed, such core 
sets have so far pertained to randomised control 
trials and trial extension studies in rheumatoid 
arthritis (RA)2 3 and have not been vetted against 
the feasibility of data collection in routine clinical 
care or against the needs of observational research. 
Indeed, any core data set to be implemented in 
registers, research cohorts or EMR systems need to 
strike a balance between clinical feasibility and the 
potential to generate useful, research-quality data.
For these reasons, a European League Against 
Rheumatism (EULAR) task force was convened to 
develop a standardised core set for data collection 
in RA that should (1) harmonise data collection in 
future observational studies, (2) act as a common 
data model against which existing databases and 
EMR systems can be mapped and (3) ensure that 
new data collections in routine clinical practice can 
support the generation of future research-quality 
data.
Methods
The task force comprised a steering committee 
(n=10, including two co-conveners (WD and JA), a 
EULAR methodologist (LG), a patient partner (CZ) 
and three fellows (HR, KC and EN)), a working 
group (additional 15 experts from 11 European 
countries and the USA, including patients, clinical 
researchers and experts in the area of epidemiology, 
quality of care and common data modelling, physi-
cians and other health professionals) and a pan-Eu-
ropean expert panel (n=90).
The task force employed a stepwise process 
(figure 1) in accordance with the EULAR standard 
operating procedure,4 underpinned by an inventory 
of data collection in existing RA clinical cohorts and 
registers.1
a. An hierarchical literature review was carried 
out by the fellows in PubMed to identify data 
items and instruments used in existing RA 
registers and clinical cohorts and the frequency 
with which these items and instruments were 
collected. Results were cross-checked with 
EULAR recommendations for reporting in 
RA clinical trials and trial extension studies2 3 
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and with the EULAR outcome measures library. Items and 
instruments felt to be missing could be added by the steering 
committee.
b. In an online survey, the expert panel rated the perceived 
importance of each of the above items (and instruments) 
to be included in a core set, using a grading scale from 1 
(not important) to 9 (very important). Again, items and 
instruments could be added.
c. At the first face-to-face meeting of the working group, 
electronic voting on individual items and instruments to 
include in the core set took place. We defined consensus 
as  ≥ 70%   of participants voting either YES or NO to the 
inclusion of a given item; if no consensus was reached, a 
second vote took place after a brief discussion which was led 
by an independent moderator (DP). In this second round, the 
threshold for consensus was lowered to  60 % . The resultant 
list of items that had reached consensus for inclusion 
informed a single round of voting on the instruments with 
which to collect information on the items.
d. Additional information on items and instruments for which 
no consensus was reached was collected. Ratification of items 
included, reasons for any exclusion and voting on items that 
had not reached consensus at the face-to-face meeting was 
performed via an online survey within the working group.
e. At the second face-to-face meeting of the working group, 
voting was conducted for outstanding items, then for final 
approval of the complete core list of items, followed by 
voting on instruments for all items in the final list using the 
same method of moderated discussion and voting cut-offs as 
outlined above.
In all voting processes, the panellists were reminded of the 
importance of striking a balance between clinical feasibility and 
the potential to generate research-quality data.
Results
literature review
Published articles from 67 different European RA registers and 
clinical cohorts were included. In total, 39 items and 125 instru-
ments were identified; eight additional items for consideration 
were added (see tables 1 and 2 in the online supplementary 
file 1).
online survey
Ninety experts from 28 different European countries including 
patients (18%), allied health professionals (18%), physicians 
(55%) and researchers (10%) participated in the survey. Twen-
ty-nine of the 47 proposed items were considered important 
enough for inclusion into a core set (see table 2 in the online 
supplementary file 1).
First face-to-face meeting
Twenty-one out of 25 (84%) members attended. In the first 
voting round, consensus for inclusion was reached for 16/47 
(34%) items and consensus for exclusion for 16/47 (34%) items. 
After discussion and a second round of voting on the remaining 
15 items, consensus was reached for inclusion of 5 and for exclu-
sion of 7, leaving two items (‘health-related quality of life’ and 
‘socioeconomic status’) without consensus (see table 2 in the 
online supplementary file 1).
Figure 1 Flow chart of the multistep process of the project. DMARD, disease-modifying antirheumatic drugs; HRQol, health-related quality of life; 
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online ratification
Twenty-three out of 25 (92%) members participated. The voting 
results from the face-to-face meeting were confirmed except for 
socioeconomic status, health-related quality of life, fatigue and 
joint surgery (lack of consensus).
second face-to-face meeting
Seventeen out of 25 (68%) members attended. Voting led to the 
exclusion of items ‘fatigue’, ‘joint surgery’ and ‘socioeconomic 
status’ but inclusion of ‘health-related quality of life’. Next, 
the resultant set of the remaining 21 items was voted on in its 
entirety and 100% of the participants agreed (see table 1 in the 
online supplementary file 1). Moderated discussion and sequen-
tial voting on the instruments with which to collect these 21 
items resulted in consensus for all but two instruments (how to 
collect data for items ‘glucocorticoids’ and ‘comorbidity’).
second online survey
A final ad hoc online survey with prespecified suggestions 
provided by the steering committee for the outstanding instru-
ments for items ‘glucocorticoids’ and ‘comorbidity’ was 
performed (see table 3 in the online supplementary file 1). Twen-
ty-one out of 25 (84%) members participated and consensus was 
reached. The final core set thus contained 21 items, each with its 
preferred instrument (see table 1).
dIscussIon
This EULAR task force has defined an RA core set, including 
both items and instruments to support standardised RA data 
collection in clinical practice and research. This will enable 
collaborative research studies and increase comparability across 
studies.
Unlike most previous core sets, this set was specifically devel-
oped keeping clinical feasibility in mind. Importantly, ‘core’ 
underscores that the set represents a minimum, acknowledging 
that individual stakeholders are likely to add items or instru-
ments of particular interest to their own data collection.
Consensus for inclusion was straightforward for the majority 
of items: 16 of the final 21 items were agreed in the first round 
of voting. Six additional items were included, and after a rati-
fication survey and discussion, ‘joint surgery’ was excluded in 
the subsequent process. Discussion for each item is summarised 
in table 3 in the online supplementary file 1. Of the 26 items 
ultimately excluded from the core data set, nine were seen as 
important by the expert group. One item, ‘fatigue’, was excluded 
from our core data set, yet is present in the Outcome Measures 
in Rheumatology (OMERACT) core outcome set for RA trials.6 
Discussion during the meeting acknowledged that this item 
was important but depending on many factors unrelated to RA 
and can be captured by the patient global assessment of disease 
activity (PGA). The group repeatedly revisited the scope of a 
core set and agreed that fatigue was a good example of an item 
that might regularly be collected in addition to the core set for 
either clinical practice or research.
The task force was established to include expertise in registers 
and observational research, clinical practice, use of EMRs, the 
patient perspective, as well as methodological expertise in the 
development of core data sets7 to enable robustness and trans-
parency. To ensure inclusiveness, all national European rheu-
matology societies were invited to contribute. Dissemination 
of the core set will be facilitated by publication online (EULAR 
website) and via national societies.
Following agreement on this core set, it is important that it is 
adopted by future observational data collections and research 
studies in RA. For EMR systems to deliver to RA research, the 
table 1 Structure and content of the RA core set developed by the 
EULAR Task Force
s. no Item
Recommendation of standardised way of 
assessment
1 Age Date of birth 
2 Gender Male/female
3 Disease duration Date of diagnosis
4 Diagnosis of RA Rheumatologist reported diagnosis of RA
5 Body mass index Weight and height
6 Smoking Current/previous/never
7 Tender joints 28 joint count
8 Swollen joints 28 joint count
9 Patient global Measured on VAS or NRS scale capturing: (1) 
global assessment of disease activity; (2) related to 
arthritis and (3) today
Example wording: ‘Considering all the ways your 
arthritis has affected you, how do you feel your 
arthritis is today?’ anchors: excellent–very poor
10 Evaluator global Measured on VAS or NRS scale capturing: (1) 
global assessment of disease activity; (2) related to 
arthritis and (3) today
Example wording: ‘What is your overall assessment 
of the patient's RA disease activity today?’ anchors: 
excellent–very poor
11 Pain Measured on VAS or NRS capturing: (1) pain; (2) 
related to arthritis and (3) last week
Example wording: ‘How much pain did you have due 
to your arthritis last week?’ anchors: no pain–worst 
imaginable pain




14 Composite scores Collection of core items 7–12 and 15 enables to 
calculate following composite scores:
 ► Clinical Disease Activity Index
 ► Simplified Disease Activity Index
 ► Disease Activity Score 28 joints
 ► EULAR response criteria
 ► American College of Rheumatology response 
criteria
15 Acute phase 
reactants
C-reactive protein AND erythrocyte sedimentation 
rate 
16 Serology Rheumatoid factor AND anticyclic citrullinated 
peptide antibodies
17 Structural damage Presence of erosions on X-ray, Yes/No
18 DMARD history Name of previous DMARD(s) (including biological, 
synthetic and targeted synthetic DMARDs)
19 Ongoing/most recent 
DMARD
Name of DMARD
Start and stop date
Reason for stopping
20 Glucocorticoids Current use of oral glucocorticoids: (1) dose taken 
today __mg prednisolone equivalent and (2) 
continuous (>3 months) intake YES/NO
21 Comorbidities Binary assessment YES/NO of the six EULAR 
comorbidity domains (cardiovascular disease, 
malignancies, infections, gastrointestinal disease, 
osteoporosis, depression)5
*Free licence available after registration for non-commercial parties according to 
www.euroqol.org.
DMARD, disease-modifying antirheumatic drugs; EULAR, European League Against 
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core set also needs to be integrated into EMR systems. Addi-
tional clinical benefits of collection of structured data such as 
informing consultations, viewing longitudinal disease progres-
sion, supporting audit and benchmarking care quality8 should be 
recognised and may encourage its clinical adoption.
In summary, through a multistep, multistakeholder and 
evidence-based process, this task force has developed an RA 
core set that may (1) harmonise data collection in future obser-
vational studies, (2) act as a common data model against which 
existing databases can be mapped and (3) serve as a template 
for standardised data collection in routine clinical practice to 
support the generation of research-quality data. This effort, 
which will continue to be updated and revised after evaluation 
of its implementation, may serve as an example for other condi-
tions beyond RA.
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